P22 | When Trial Design Meets Approved Maintenance: A Single-Center Real-World Experience With Dara-VTD Induction and Consolidation Followed by Lenalidomide Maintenance in Transplant-Eligible Multiple Myeloma
Single-center experience shows excellent outcomes with Dara-VTd induction and lenalidomide maintenance in multiple myeloma, suggesting need for alternatives in high-risk patients.
Key Points
To analyze outcomes of lenalidomide maintenance following Dara-VTd induction in multiple myeloma patients.
Retrospective analysis of 103 newly diagnosed transplant-eligible multiple myeloma patients.
Treatment regimen included Dara-VTd induction, ASCT, Dara-VTd consolidation, followed by lenalidomide maintenance.
MRD assessed by 8-color flow cytometry before maintenance and after one year.
Analysis included response rates, progression-free survival (PFS), and overall survival (OS).
Overall 2-year PFS and OS were 83% and 91%, respectively.
MRD negativity was observed in 67% of patients before maintenance.
Significantly longer 2-year PFS (98% vs 67%) and OS (100% vs 67%) in MRD-negative vs MRD-positive patients.
Patients with high-risk cytogenetics had worse 2-year PFS (64% vs 87%) and OS (73% vs 95%).